众华会计师事务所（特殊普通合伙） 对《关于对上海润达医疗科技股份有限公司 2024 年度报告的 事后审核问询函》中相关问题的专项说明 众华会计师事务所（特殊普通合伙） 对《关于对上海润达医疗科技股份有限公司 2024 年度报告的事 后审核问询函》中相关问题的专项说明 众会字（2025）第 09689 号 上海证券交易所： 众华会计师事务所（特殊普通合伙）（以下简称"我们"）接受委托对上海 润达医疗科技股份有限公司（以下简称"公司"）2024 年财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、合并 及公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注进行审 计，并于 2025 年 4 月 24 日出具了众会字(2025)第 04148 号的无保留意见审计报 告。 我们于近日收到了公司转来的贵所出具的《关于对上海润达医疗科技股份 有限公司 2024 年度报告的事后审核问询函》（上证公函【2025】0796 号）（以下 简称《问询函》）。我们根据问询函的要求对问询函中与财务会计相关的问题进 行了核查，回复如下： 一、关于经营业绩。年报显示，报告期内 ...

Group 1 - The company announced a cash dividend distribution plan for the year 2024, proposing a distribution of 0.30 yuan (including tax) for every 10 shares held by shareholders, based on the total share capital registered on the equity distribution record date [1][2] - The plan was approved at the company's annual general meeting held on May 27, 2025, and will be implemented following the equity distribution record date [1][2] - The convertible bond "Runda Convertible Bond" will suspend conversion from July 10, 2025, until the equity distribution is completed, with resumption of conversion on the first trading day after the record date [1][2] Group 2 - The company will adjust the conversion price of the "Runda Convertible Bond" in accordance with the terms outlined in the bond issuance prospectus after the equity distribution is implemented [2] - Shareholders and convertible bondholders are advised to refer to the announcements published on the Shanghai Stock Exchange website and relevant financial newspapers for further details [2]

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-034 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于实施 2024 年度权益分派时转股连续停牌的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施 2024 年度权益分派,本公司的相关证券停复牌情况如下： 本次权益分派方案实施后，公司将根据《上海润达医疗科技股份有限公司公 开发行可转换公司债募集说明书》的发行条款及相关规定，对"润达转债"当期 转股价格进行调整。 二、本次权益分派方案实施时转股连续停牌的安排 1、公司将于2025年7月11日在《中国证券报》、《上海证券报》、《证券日 报》、《证券时报》及上海证券交易所网站（www.sse.com.cn）上发布权益分派 实施公告和可转债转股价格调整公告。 2、自 2025 年 7 月 10 日至权益分派股权登记日期间，"润达转债"将停止转 股，股权登记日后 ...

| | | 上海润达医疗科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司本次发行的"润达转债"的转股期为 2020 年 12 月 23 日至 2026 年 6 月 16 日。 在 2025 年 4 月 1 日至 2025 年 6 月 30 日期间，共有人民币 180,000 元的"润 达转债"已转换成公司股份，转股数量为 13,839 股。截至 2025 年 6 月 30 日， 累计人民币 315,655,000 元的"润达转债"转换成公司股份，占可转债发行总量 57.3918%，累计转股数量为 24,130,185 股，占可转债转股前公司已发行股份总额 的 4.1637%。 截至 2025 年 6 月 30 日，尚未转股的"润达转债"金额为人民币 234,345,000 元，占可转债发行总量的 42.6082%。 三、股本变动情况 单位：股 一、可转债发行上市概况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限 ...

上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-033 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 担保对象及基本情况 | 资产负债率为 | | 70%以上的全资及控股子公司 | | | | | --- | --- | --- | --- | --- | --- | | 担 保 | 对 | 被担保人名称 | | 杭州润达医疗管理有限公司 | | | | | 本次担保金额 | 16,592 | 万元 | | | 象一 | | 实际为其提供的担保余额 | 166,607.44 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | 担 保 | 对 | 被担保人名称 ...

Group 1 - The company's主体信用等级 is maintained at "AA" with a stable rating outlook [1][2] - The credit ratings for the issued "润达转债" and "23 润达医疗 MTN001" are also maintained at "AA" [1][2] - The credit rating agency, 新世纪评估, conducted a comprehensive analysis of the company's industry and operational status before confirming the ratings [2]

Core Viewpoint - The company, Shanghai RunDa Medical Technology Co., Ltd., is positioned well in the in-vitro diagnostic (IVD) market, benefiting from strong demand driven by economic growth, aging population, and upgrading medical consumption structure [1][3][6]. Company Overview - RunDa Medical focuses on the IVD sector, establishing a nationwide business layout and accumulating a significant customer and supplier base [1][3]. - The company has introduced state-owned capital as a controlling shareholder, enhancing its financial channels and collaboration with public healthcare institutions [3][6]. Market Environment - The IVD market is characterized by strong demand due to factors such as economic growth, an aging population, and increased healthcare spending [6][8]. - The industry faces challenges from regulatory changes and intense competition, which may impact revenue and profitability [3][6][8]. Financial Performance - The company's revenue has shown a decline, with total revenue for 2024 at 83.06 billion, down from 91.40 billion in 2023, reflecting a 9.13% decrease [8][9]. - The gross profit margin has also decreased, with a comprehensive gross margin of 25.37% in 2024 compared to 26.58% in 2023 [8][9]. Business Operations - RunDa Medical operates two main business segments: commercial comprehensive services and industrial services, with the commercial segment contributing over 90% of total revenue [10][12]. - The company has expanded its service offerings to include AI medical solutions, collaborating with major hospitals and healthcare institutions [9][10]. Competitive Position - The company has established a robust supply chain with over 1,200 suppliers and nearly 19,000 product varieties, ensuring comprehensive coverage of the IVD market [19][20]. - RunDa Medical's focus on R&D in IVD products and digital solutions positions it competitively within the industry [20]. Future Outlook - The company anticipates stable credit quality in the coming months, although potential downgrades may occur due to significant performance deterioration or changes in major stakeholders [3][4]. - Continued investment in AI and digital health solutions is expected to enhance market competitiveness and operational efficiency [9][10].

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-031 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于"润达转债"与"23 润达医疗 MTN001" 2025 年跟踪评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司前次主体信用评级结果为"AA"，评级展望为"稳定"。"润达转债"前次评 级结果为"AA"，评级时间为 2024 年 6 月 26 日。"23 润达医疗 MTN001"前次评级 结果为"AA "，评级时间为 2024 年 6 月 26 日。评级机构均为新世纪评估。 新世纪评估在对公司所属行业及经营状况等进行综合分析与评估的基础上，于 2025 年 6 月 25 日出具了《上海润达医疗科技股份有限公司及其发行的润达转债与 23 润达医疗 MTN001 定期跟踪评级报告》【新世纪跟踪（2025）100175】，维持公司"AA" 的主体信用等级，评级展望维持"稳定"，同时维持"润达转 ...

内部编号:2025060241 上海润达医疗科技股份有限公司 及其发行的润达转债与 23 润达医疗 MTN001 定期跟踪评级报告 | 项目负责人: 能 腔 | Rectif | xh@shxs j. com | | --- | --- | --- | | 嵇敏珍 项目组成员: | 2222000 | jiminzhen@shxsj.com | | 张明海 评级总监: | 82-16 | | | 联系电话:(021)63501349 | | | | 联系地址:上海市黄浦区汉口路 398 号华盛大厦 14 层 | | | | 公司网站:www.shxsj.com | | | 上海新世纪资信评估投资服务有限公司 Shanghai Brilliance Credit Rating & Investors Service Co., Ltd. 声明 除因本次评级事项使本评级机构与评级对象构成委托关系外,本评级机构、评级人员与评级对象不存在任何影响 评级行为独立、客观、公正的关联关系。 本评级机构与评级人员履行了调查和诚信义务，所出具的评级报告遵循了真实、客观、公正的原则。 本报告的评级结论是本评级机构依据合理的内部信用 ...

Core Viewpoint - The article highlights the significant achievements of the Run Medical Model, developed based on the Pangu large model, in the field of AI and healthcare, establishing a new benchmark for AI+medical applications [1][6][10]. Summary by Sections MedBench Evaluation - The Run Medical Model topped the MedBench evaluation platform with scores of 96.4 and 93.2 in the professional and self-assessment categories, respectively, showcasing its leading position in the medical AI sector [3][4][8]. - In the self-assessment category, the model excelled in four dimensions: medical knowledge Q&A (91.2), medical language generation (85.1), medical language understanding (123.1), and medical safety and ethics (106.6) [4][8]. - The model also performed well in the professional evaluation, achieving scores of 87.7, 84.8, 122.4, and 98.7 in the same respective categories [4][8]. Technical Innovations - The Pangu model team utilized a vast dataset, including hundreds of billions of high-quality Chinese and English medical literature, guidelines, and millions of health records, to enhance the Run Medical Model's medical knowledge and expression capabilities [8][9]. - A multi-agent medical data synthesis workflow was introduced to improve the model's ability to capture complex patterns and relationships in medical data, enhancing its Q&A, language generation, and reasoning capabilities [9][10]. Industry Impact - The advancements in the Run Medical Model are seen as a significant milestone in the development of medical AI, reflecting the team's deep technical accumulation and innovative strength in the medical vertical [8][10]. - The Pangu model serves as a powerful foundation for medical AI, driving the industry towards a new era of intelligent, precise, and personalized healthcare [10].